 |
 |
 |
|
|
|
April 29th, 2008
Aldosterone: New Insights in Kidney Health and Disease 
David A. Calhoun, MD and Mark E. Rosenberg, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Calhoun: In normotensive individuals, how do aldo levels affect the risk of incident hypertension? What is the prevalence of aldosteronism in mild, moderate, and severe or resistant hypotension? What percent of this is due to adenoma? How effective is spironolactone as an anti-hypertensive drug? By how much does it lower blood pressure? Is spironolactone more effective in those patients with primary hyperaldosteronism? What is the risk of hyperkalemia with spironolactone, and how can this be mitigated? Rosenberg: What does the animal data show about use of aldosterone blockers in various animal models of CKD and/or renal injury? What do the clinical studies of spironolactone in CKD show? At what level of GFR do we need to start monitoring most closely for hyperkalemia? In 2008, can the use of aldosterone antagonists for CKD progression prevention be recommended?
Management of Hyperphosphatemia in Patients with ESRD: A New Direction for Treatment in 2008 
Wajeh Qunibi, MD, and Charles Nolan, MD
(CME Symposium (Medical Education Resources), January, 2008.)
Qunibi: How do sevelamer and calcium acetate compare in terms of phosphate control? In terms of grams of binder needed to achieve equivalent phosphate control? The explanation for reduced progression rate of vascular calcification in the RIND and DCOR studies has been lack of calcium-loading with sevelamer. To what extent is an alternative hypothesis, that of lowering of LDL- cholesterol, consistent with the data? What are data in animal models regarding vascular calcification in CKD and the effect of calcium-based phosphate binders? In the CARE-2 study (now available on-line at the AJKD website) progression of calcification was compared between calcium acetate plus atorvastatin and sevelamer plus atorvastatin (as needed to achieve equivalent LDL levels). What were the principal findings of CARE-2? Nolan: What did Treat-to-Goal, DCOR, RIND, DCOR Revisited, and CARE-2 show with respect to both calcification and mortality? How were the mortality results different from the calcification results? What are the DOPPS data with regard to phosphate binder use and mortality? What percentage of patients do the KDOQI guidelines recommend for non-calcium containing phosphate binders? What are the relative costs of sevelamer, calcium acetate, and calcium carbonate?
RRI Tenth International Conference on Dialysis, January, 2008. Part Three.
(Renal Research Institute 10th International Conference)
Flash slide/audio; MP3 audio
Angiotensin II, interstitial inflammation and the pathogenesis of salt sensitive hypertension
Martha Franco, MD, PhD
How common is malnutrition in ESRD? An approach to diagnosis and management
Martin Kuhlmann, MD
Blind Pugh sends a black spot: The current hemoglobin controversy
Paul E. Stevens, MB, FRCP
KEYNOTE ADDRESS: The metabolic syndrome and kidney disease
Eberhard Ritz, MD
Transplant and CKD patients at the same stage of renal insufficiency: how are they the same or different?
Warren Kupin, MD, FACP
The Future is Your Business. Preparing for Changes in Nephrology Practice. Part One of Three.
Flash - slide/audio and MP3/WMA audio
(RPA Annual Meeting, March, 2008.)
This is free to RPA members. Please look at the RPA members only section on the RPA website for access instructions.
RPA: Year in Review
Alan Kliger, MD
RPA's Advocacy Agenda
Robert Blaser, MD
Brian Ling Lecture: Pay for Performance is Here! Lessons of success from Medicare Physician Payment Demonstration Project
Karl Ulrich, MD
ESA Payment Update: Where Knowledge Meets Politics
Alan Nissenson, MD
Value and Courage in Politics: Nephrology Reaches Farther
Rebecca Schmidt, MD
Value and Courage in Politics: Nephrology Reaches Farther
Larry Lehrner, MD
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
INTERVENTIONAL NEPHROLOGY: WHAT NEPHROLOGISTS SHOULD KNOW (Part 2 of 2)
Complications of Tunneled HD Catheters
Antoine L. Samaha, MD
Management of Catheter Infection
Bharat S. Sachdeva, MD
Peritoneal Dialysis Catheters: Peritoneoscopic Method
Stephen R. Ash, MD
Peritoneal Dialysis Catheters: Fluoroscopic Method
Ivan D. Maya, MD
Percutaneous Balloon Angioplasty Procedure
Alexander S. Yevzlin, MD
Management of Central Venous Stenosis
Florin N. Gadalean, MD
Hand Ischemia
Steven Wu, MD
Preservation of Veins?
Edgar V. Lerma, MD, FASN
Evaluation Stents: Do They Work?
Kenneth D. Abreo, MD
Vascular Access Center: What Does It Mean for You and What Does It Do for the Patient?
Donald Schon, MD
April 16th, 2008
Pre-ESRD and Mineral Metabolism
Kevin J. Martin, MB, BCh, BAO, FACP, and Sharon M. Moe, MD, FASN
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Martin: What is the time course of changes in 1,25D in patients with CKD as GFR falls? What are their 25D levels? How does nephrotic syndrome affect 25D levels? What is the animal data regarding use of calcitriol or other D-derivatives in models of CKD and/or renal injury? Does vitamin D protect or harm the kidney? What is the data in patients regarding vitamin D and progression of CKD? Moe: How does FGF-23 fit into the picture of mineral bone disorder? What is the most important action of FGF-23 in terms of renal osteodystrophy? How important are minor phosphorus elevations in normal patients and in patients with very mild CKD? How does serum Pi relate to cardiovascular events and progression in early CKD patients? What are the data regarding osteoporosis in CKD patients? What do bone biopsy data show? Is osteoporosis greater with hyperparathyroid bone disease or adynamic? What role does hypogonadism play? What is the new proposed KDIGO classification? What are the correlates of osteoporosis in CKD patients?
RRI Tenth International Conference on Dialysis, January, 2008. Part Two.
Flash slide/audio; MP3 audio
Heart rate variability and sympathetic function in CKD-implications for management
Christopher T. Chan, MD, FRCPC
Obesity in the dialysis patient - good or bad?
Jonas Axelsson, MD, PhD
Potential interventions in sepsis-related acute renal failure
Claudio Ronco, MD
Debate Part I CKD Stage V in the aged population (>70 yrs): dialysis or (low protein) diet?
Madhukar Misra MD, FACP
Debate Part II CKD Stage V in the aged population (>70 yrs): dialysis or (low protein) diet?
Giuliano Brunori, MD
(Renal Research Institute 10th International Conference. January, 2008.)
ANNA CE
(Article Free, $CE)ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.
Relationships Between Registered Nurse Staffing, Processes of Nursing Care, and Nurse-Reported Patient Outcomes in Chronic Hemodialysis Units
(Vol 35/No. 2. Expires 04/20/2010)
Charlotte Thomas-Hawkins, PhD, RN; Linda Flynn, PhD, RN; Sean P. Clarke, PhD, CRNP, FAAN
1.4 hr
The Self-Management Experience Of People with Mild to Moderate Chronic Kidney Disease
(Vol 35/No. 2. Expires 04/20/2010)
Lucia Costantini, MN, RN; Heather Beanlands, PhD, RN; Elizabeth McCay, PhD, RN; Daniel Cattran, MD; Michelle Hladunewich, MD; Daphene Francis, BScN, RN
1.5 hr
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
INTERVENTIONAL NEPHROLOGY: WHAT NEPHROLOGISTS SHOULD KNOW (Part 1 of 2)
Vascular Anatomy: What Should Nephrologists Know about It?
Gerald A. Beathard, MD, PhD, FASN
Vascular Mapping: Is It Needed?
Arif Asif, MD
Sites and Types of Arteriovenous Fistulae
Gerald A. Beathard, MD, PhD, FASN
Early Arteriovenous Fistula Failure: Basic Biology and Hemodynamics
Prabir Roy-Chaudhury, MD, PhD, FASN
Fistula Maturation and Its Timing
Bhagwan D. Bhimani, MD
Vascular Access Surveillance: Detection of Access Malfunction
Anatole Besarab, MD
Salvage of an Immature Fistula
Jack Work, MD
Fistula Thrombosis and Thrombectomy Procedures
Naveen K. Atray, MD, FASN
Graft Thrombectomy: What is the Best Method?
Aris Q. Urbanes, MD
Creation of Secondary Fistula
Peter L. Miller, MD
Does Cannulation Make a Difference?
Deborah J. Brouwer, RN, CNN
Renal Ultrasound
W. Charles O'Neill, MD
March 31st, 2008
New Insights into Common Problems After Kidney Transplantation
Bertram L. Kasiske, MD and Jose R. Weisinger, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Kasiske: Which forms of cancer are increased after renal transplantation, and what explanations account for these increases? Are there any particular immunosuppressive regimens associated with a higher or lower incidence of cancer? If so, which ones? Weisinger: What characterizes post-transplant bone disease? What happens typically to parathyroid hormone? To serum phosphorus? Should the hypophosphatemia be treated? How are phosphatonins involved? What do we know from bone biopsy studies? What are reasonable short and long term strategies to minimize bone loss after transplantation? What evidence will KDIGO be reviewing in this area?
RRI Tenth International Conference on Dialysis, January, 2008. Part One.
Flash slide/audio; MP3 audio
What a nephrologist should understand about a dialysis machine
Richard A. Ward, PhD
How water quality & dialysate composition affect dialysis practice
Nicholas A. Hoenich, PhD
Understanding the Federal ESRD survey process: current issues & future directions
Judith Kari, MSSW
Understanding the finances of a dialysis facility and its medical director
Peter B. DeOreo, MD, FACP
How dialysis membranes can affect outcome - new developments
Norma Ofsthun, PhD
CASE DISCUSSION: A complex PD patient
Jose A. Diaz-Buxo, MD, FACP
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
GLOMERULONEPHRITIS UPDATE: DIAGNOSIS AND THERAPY (PART 2 OF 2) - 9 talks
ANCA Small Vessel Vasculitis
Patrick H. Nachman, MD
Diagnosis and Treatment of Anti-GBM Disease
Charles D. Pusey, DSc, FRCP
Case study : Treatment Issues in Rapidly Progressive Glomerulonephritis: Variations on Transatlantic Themes
Faculty
The Dysproteinemias
Stephen M. Korbet, MD, FASN
Current and New Treatments of Lupus Nephritis
Gerald B. Appel, MD, FASN
Thrombotic Microangiopathies
Gerald B. Appel, MD, FASN
Viral Glomerulonephritides: HIV, HBV, and HCV
Warren L. Kupin, MD
Case study : Management Cases in Lupus Nephritis, Viral Glomerulonephritis, and Dysproteinemias
Faculty
March 14th, 2008
Challenges and Opportunities in the Treatment of Hyperuricemia and Gout
Richard Johnson, MD (moderator); Robert Terkeltaub, MD; Michael W. Rich, MD; Daniel Feig, MD, PhD, MS
(ASN Renal Week Official Symposium, 2007).
Terkeltaub: What are the available treatments for gout? What is the mechanism of action of allopurinol? What are the cautions associated with its use? How is febuxostat different and possibly better? How do uricosurics work? Which ones are available? What are the pros and cons of uricases? Rich: Elevated uric acid is associated with poor cardiovascular outcomes. What evidence suggests that this may be causal? What were the findings regarding serum uric acid in the SHEP study? How does uric acid figure in studies of congestive heart failure or coronary artery disease? What do interventional studies using allopurinol tell us? Did the uricosuric effect of losartan affect outcomes in the LIFE study? Feig: What does a rat model of uricase inhibition show in terms of blood pressure and salt sensitivity? What does raising uric acid do to glomerular pathology? What is true of serum uric acid in essential hypertension in adolescents? What happens when you give half of them allopurinol?
New Treatments for Diabetes Mellitus: Implications for Clinicians
Robert Nelson, MD and George Bakris, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Nelson: How do we treat diabetes with kidney disease in 2007? What does KDOQI recommend in terms of screening? Blood pressure targets? What are the current recommendations regarding ACE inhibitors and ARBs? What should the target HbA1C be? What protein intake? What LDL value? What are the trends in terms of obesity and diabetes in children? What does study of Pima Indians teach us? Bakris: What are the major classes of PPARs and what are their physiologic effects? Can thiazolidinediones (TZDs) actually prevent diabetes? What are the data in terms of diabetes progression? How do outcomes differ short term vs. long term? How useful are combinations of metformin plus TZDs, or sulfonylureas plus TZDs? What are the intermediate cardiovascular and lipid effects and effects on microalbuminuria? What did the PROactive trial show? Was the Nissen NEJM meta-analysis flawed? What are the current FDA recommendations and cautions?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
GLOMERULONEPHRITIS UPDATE: DIAGNOSIS AND THERAPY (PART 1 OF 2) - 9 talks
Management of the Nephrotic Syndrome
Gerald B. Appel, MD, FASN
Pathology and Pathogenesis of Minimal Change Disease and Focal Segmental Glomerulosclerosis
Helmut G. Rennke, MD
Membranous Nephropathy in 2007
Daniel C. Cattran, MD, FRCPC
Treatment of Focal Segmental Glomerulosclerosis
Stephen M. Korbet, MD, FASN
Case study : Treatment Issues in Focal Segmental Glomerulosclerosis
Faculty
Spectrum of Membranoproliferative Glomerulonephritis
Helmut G. Rennke, MD
Treatment and Pathology of Diabetic Nephropathy in 2007
J. Charles Jennette, MD; Jai Radhakrishnan, MD
IgA Nephropathy: 2007 Update
Richard J. Glassock, MD
Case study : Management Cases of Membranous, IgA Nephropathy, and Membranoproliferative Glomerulonephritis
Faculty
February 28th, 2008
Medical Crossfire: Managing Phosphorus in CKD -- The Challenge Remains
David Bushinsky, MD (moderator); Geoffrey Block, MD, CCRI; Francisco Llach, MD; Rajnish Mehrotra, MD, FACP, FASN.
(ASN Renal Week Official Symposium, 2007).
Panel Discussion: What are the factors that promote vascular calcification in early CKD and in ESRD? How does vascular calcification affect prognosis? Should we screen for vascular calcification? If so, how? If yes, then how do we use this information? What should the target serum phosphate levels be as CKD progresses from stage 3 through 5? How good is the data suggesting lower phosphate targets? What are the various phosphate binder options available? Are they equally effective? Equally potent? Are there patient factors affecting choice of binder? To what extent should we control serum phosphate in predialysis patient? How should this be done? What are the key take-home points?
The Aging Kidney
Danilo Fliser, MD; George R. Aronoff, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Fliser: How fast does GFR fall as we age? If GFR the best measure of renal function in the elderly? What other changes occur in the kidneys as we age? How is the fall in GFR related to comorbidity? To what extent is cystatin a better measure of GFR in the elderly? Aronoff: How do we approach drug dosing in the elderly? What happens to body composition and how does this affect dose? Is liver metabolism of drugs affected? If so, how? What about pharmacodynamics? What is the Beers list of drugs? Which drugs are best avoided in the elderly? What are practical ways of reducing drug exposure in this population?
ANNA CE
(Article Free, $CE)Learning from Stories of People with Chronic Kidney Disease
(Vol 35/No. 1. Expires 02/20/2010)
Anita E. Molzahn, PhD, RN; Anne Bruce, PhD, RN; Laurene Sheilds, PhD, RN
1.3 hr
Cognitive Function and Adherence of Older Adults Undergoing Hemodialysis
(Vol 35/No. 1. Expires 02/20/2010)
Debra J. Hain, DNS, ARNP, GNP, BC
1.4 hr
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
CRITICALLY APPROACHING THE LITERATURE: APPLYING THE PRINCIPLES OF EPIDEMIOLOGY AND BIOSTATISTICS (Part 2 of 2)
Principles of Bioethics: Justifying Research
Bernard Lo, MD
Debate: Does Routine Screening of Dialysis Access Reduce Risk of Thrombosis?
Laura M. Dember, MD, FASN
Decision Analysis and Cost-Effectiveness Analysis: Taking It to Another Level
Neil R. Powe, MD, MPH, MBA, FASN
Genetic Epidemiology: A New Frontier
Donald W. Bowden, PhD
Putting It All Together: Journal Club #2
Kirsten L. Johansen, MD
Biostatistics Workshop Part #2: Everything You Always Wanted to Know About Biostatistics, But Were Afraid to Ask
Charles E. McCulloch, PhD
February 15th, 2008
Phosphate Binders in CKD: An Update on Treatment Outcomes and Future Directions
Gérard M. London, MD (moderator): Craig B. Langman, MD; Markus Ketteler, MD.
(ASN Renal Week Official Symposium, 2007).
Langman: What is the pathogenesis of mineral bone disorder in CKD? As GFR falls, at what point does serum Pi increase? What is the comparative efficacy of currently used Pi binders? What's the association between serum Pi levels and cardiovascular risk in ESRD, stage 2-4 CKD, and stage 2 CKD? What percent have coronary calcification at onset of dialysis? What were the conclusions of the DCOR and RIND studies in terms of coronary calcification and survival in patients using sevelamer vs. calcium-containing binders? What are the new data concerning sevelamer carbonate? Ketteler: What is fibroblast growth factor 23, and what is its role in phosphate excretion as GFR falls? How does extracellular phosphate affect vascular smooth muscle biology? What are the pathways for activating vascular smooth muscle transformation into osteoblast phenotypes? What does fetuin-A do? How does sevelamer affect fetuin-A levels? What is the role of matrix Gla protein and pyrophosphate in preventing calcification?
Challenges in Volume Management. Optimizing Care in Patients with Heart Failure and Renal Dysfunction
John C. Burnett, MD; Michael B. Fowler, MBBS, FRCP; Mihai Gheorghiade, MD
(ASN Renal Week Official Symposium, 2007).
Burnett: What is the prevalence of CKD in patients with CHF? What is the cardiorenal syndrome? What are its principal mechanisms? How are ANP and BNP involved? How is BNP activation impaired in CHF? How are aldosterone and AVP involved in heart failure? Fowler: Which of the common pharmacologic treatments for heart failure impact on survival and other hard outcomes? Digoxin? Diuretics? Beta-blockers? ACE-I, ARB? Aldosterone blockers? Nitrates-hydralazine? Do implantable defibrillators improve survival? What is the risk-predictive value of a widened QRS interval? What is cardiac resynchronization therapy? What are new treatment methods on the horizon, including vasopressin antagonists, adenosine antagonists, aliskiren, and newer intotropic agents? Gheorghiade: What is the role of pulmonary congestion in heart failure? What are the therapeutic options? How do treatments with diuretics vs. vasopressin antagonists differ in terms of effects on urinary parameters and serum sodium? What is the prognostic importance of hyponatremia in heart failure? What do the treatment trials with vasopressin antagonists, especially using tolvaptan, show in terms of both intermediate and hard outcomes?
Cardiovascular Disease in End Stage Renal Disease Patients
William L. Henrich, MD, MACP.
(ASN Board Review Course, August, 2007.)
Henrich: What are the main cardiovascular risks in patients with CKD? What are the proposed mechanisms of LVH, including concentric and eccentric hypertrophy, and systolic and diastolic dysfunction? What are the causes for sudden death? What is the role of myocardial intermyocyte fibrosis? What did the fosinopril and ramipril trials show? Are biomarkers useful? Why was the 4-D trial negative? Are statins useful in early CKD? What is the role for carvedilol? More frequent dialysis? Is there an advantage for CABG over stents in ESRD patients? What are the basic management guidelines for cardiovascular disease in CKD patients?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
CRITICALLY APPROACHING THE LITERATURE: APPLYING THE PRINCIPLES OF EPIDEMIOLOGY AND BIOSTATISTICS (Part 1 of 2)
E is for Epidemiology: The Key Principles
Harold I. Feldman, MD, FASN
Case-Control Studies: Low Cost/High Impact
Rulan S. Parekh, MD, FASN
Cohort Studies: From the Beginning to the End
Ravi I. Thadhani, MD, MPH
Randomized Controlled Trials: Good as Gold
Christoph Wanner, MD
Biostatistics Workshop Part #1: How Things Actually Work
Tom H. Greene, PhD
Biostatistics Workshop Part #2: How Things Actually Work
Tom H. Greene, PhD
Meta-Analysis: When One is Not Enough
Amit Garg, MD, PhD
Putting It All Together: Journal Club #1
Mary B. Leonard, MD
January 30th, 2008
Contrast Media and CKD: What You Should Know About Contrast-Induced Nephropathy and Nephrogenic Systemic Fibrosis
Norbert Lameire, MD (moderator); Pontus B. Persson, MD, PhD; Michael V. Knopp, MD, PhD; Mark A. Perazella, MD
(ASN Renal Week Official Symposium, 2007).
Persson: What is the definition of contrast-induced nephropathy (CIN)? How can an acute decrease in GFR result in a creatinine elevation that peaks several days later? Is it the osmolality of these agents or their viscosity that's at fault? How do they cause renal damage? How do the affect blood flow through the vasa recta? Tubuloglomerular feedback? What is the osmolality and viscosity of commonly used contrast agents? What do clinical studies tell us? Why is renal failure lower with a low-osmolar, but above iso-isosmolar, agent (ioxaglate) compared to an isosmolar agent (iodixanol)? Knopp: What are the choices of imaging procedures in renally impaired patients? How do we use them to assess morphology and function? What are the main categories of MR contrast agents? Perazella: How is nephrogenic systemic fibrosis (NSF) defined? When was it first noticed? What are the symptoms? What parts of the body are affected? Which parts are spared? What are predisposing causes? Does it occur in stage 1-4 CKD? How do we diagnose NSF? With which MR agents is it most common? Least common? What guidelines can we follow in using these agents?
New Developments in Anemia Management in Chronic Kidney Disease
Dr. Adeera Levin, MD (moderator): Cindy Roy, PhD; Anatole Besarab, MD; Richard Amerling, MD, Arnold Berns, MD (discussant)
(ASN Renal Week Official Symposium, 2007).
Roy: How dose iron cycle through the various organs? Where does hepcidin get involved? What is ferroportin? What does hepcidin to to macrophage transport of iron? To iron absorption? What can we learn from transgenic rat models?
Besarab: How has our target Hb evolved as guidelines have been issued over the past 10 years? What is the FDA target? The 2007 KDOQI target? What did the Normalized Hemoglobin Trial, CREATE, and CHOIR show? How can we achieve Hb targets while minimizing cycling? What does KDOQI recommend in patients with ferritins greater than 500? What happened in the DRIVE study, where iron was given to patients with ferritins of 500-1200 ng/mL?
Amerling: When 1 g of ferric gluconate was given to 80 dialysis patients with serum ferritins ranging from 100 - 1500 ng/mL, what where the results on Hb, TSAT, and serum ferritin? What effect did this have on ESA dose?
The Cystic Diseases
William M. Bennett, MD.
(ASN Board Review Course, August, 2007.)
Bennett: What are the basis of PKD genetics? Clinically, how do ADPKD1, ADPKD2, and ARPKD differ? How do we diagnose PKD? When are ultrasounds falsely negative? Genetic tests? What part of the cell is affected by polycystin? What is the 2-hit theory? What are the renal complications? How should hypertension be treated? What are the cerebrovascular and cardiovascular complications? When should we screen for CV aneurysms? What are the liver and GI complications? What did we learn from the CRISP study about progression? What are the new treatments for PKD? what conditions can cause similar cystic disease in the kidney? What other renal cystic diseases are of importance?
Biopsy Conference: A middle-aged Hispanic male with microhematuria and proteinuria
(Columbia University Nephrology and Pathology Faculty; January, 2008)
A middle-aged Hispanic male had with history of incarceration, occupation as a welder, heroin abuse, presented with proteinuria 3.4 g/day and microhematuria. No DM. Mild HTN. Normal sized kidneys. Negative serological tests. Initial DDx: Membranous, IgA, FSGS. Discussion focus: Hint: IgG deposits were found.
(Edited by Jai Radhakrishnan, MD). (more...)
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
CRITICAL CARE NEPHROLOGY: 2007 UPDATE (Part 2 of 2)
Defining AKI
Ravindra L. Mehta, MD, FASN
Pathophysiology of AKI
Bruce A. Molitoris, MD
Pharmacologic Therapy for AKI
Mark D. Okusa, MD, FASN
Contrast-Induced Nephropathy
Paul M. Palevsky, MD, FASN
Abdominal Compartment Syndrome
Lakhmir S. Chawla, MD
Renal Replacement Therapy in AKI: When, What, and How Much
Paul M. Palevsky, MD, FASN
The Hybrid Renal Replacement Therapies
Mark R. Marshall, MBChB
Technical Issues for the Delivery of RRT in the ICU
Paul M. Palevsky, MD, FASN
Pediatric AKI
Stuart Goldstein, MD
Drug Dosing in AKI
Bruce A. Mueller, PharmD
Treatment of Poisonings
David S. Goldfarb, MD, FASN
January 15th, 2008
Navigating the Erythropoietin Stimulating Agent Landscape in CKD-Related Anemia
Jeffrey S. Berns, MD, FASN; Robert Provenzano, MD; Lynda Szczech, MD. (Moderator: Jeffrey S. Berns, MD)
(ASN Renal Week Official Symposium, 2007).
Berns: What does the recent literature show? CHOIR, CREATE, ACORD, MacDougall, and the 2007 KDOQI workgroup meta-analyses?
Provenzano: How were these issues discussed at the Cardiovascular and Renal Drugs Advisory Committee on ESAs? What were the votes regarding each practice recommendation? What were open questions?
Szczech: Now that the FDA has mandated new black box warnings on ESAs, how does impact our use of these agents? How can we minimize potential side effects of ESAs? What might be our triggers for action? What should the initial dosages be, and when should doses be reduced or held?
Critical Care Nephrology
Patrick Murray, MD.
(ASN Board Review Course, August, 2007.)
Murray: How do we hemodynamically manage sepsis in terms of MAP, CVP, urine output, and mvO2? How can we optimize renal perfusion? Is there evidence that any of the inotropes are better? What should the target MAP be? What are the results regarding vasopressin? Drotrecogin alpha? Corticosteroid use? What is the ideal ventilator strategy, and what are the main pulmonary-renal syndromes? What do the data show about dry vs. wet management?
ANNA CE
Lecture Free
Free CE
Chronic Kidney Disease - Mineral Bone Disorder
Jose A.L. Arruda, MD, FASN; Jennifer L. Snavely, CRNP-BC, MSN, CNN)
(ANNA Fall Meeting, San Francisco, CA. October, 2007.) 1.25 CE
Arruda: What do observational data suggest about desirable levels of serum PTH, calcium, and phosphorus in CKD patients? What do the vitamin D studies show? Are the analogues different from calcitriol in terms of survival? When is cinacalcet indicated? How does vascular calcification relate to mortality? What did the Treat-to-Goal, RIND, and DCOR studies tell us about calcium-containing phosphate binders versus sevelamer? Snavely: How do we define CKD-Bone Mineral Disorder? As CKD progresses, when do changes in calcium, phosphorus, and PTH occur? How is vitamin D involved? What to the KDOQI clinical practice guidelines suggest in terms of managing elevated PTH as GFR falls? When should we give vitamin D and in what form? What are the practice barriers in addressing bone mineral disorders in CKD patients?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
CRITICAL CARE NEPHROLOGY: 2007 UPDATE (Part 1 of 2)
Ventilators 101: What the Non-Intensivist Needs to Know
Patrick T. Murray, MD, FASN
Acute Lung Injury/ARDS
Kathleen D. Liu, MD
Hemodynamic Monitoring and Volume Management
Lakhmir S. Chawla, MD
Approach to Shock, Vasopressors, and Natriuretic Peptides
Kathleen D. Liu, MD
Advances in the Treatment of Severe Sepsis and Septic Shock
Patrick T. Murray, MD, FASN
An Update on Congestive Heart Failure
Kiran K. Khush, MD
Update in Coagulation: Cell Mediated Coagulation and New Anticoagulants
Lakhmir S. Chawla, MD
Current State of Acute Brain Injury Management
Andrew Davenport, MD
Ethics in the ICU: When Can You Say No?
Douglas B. White, MD, MAS
HDCN home /about our site / subscribe to key zone / register for free zone
update email
address / subscription status / forget your
password?
